What the Evidence Says About Psychedelic-Assisted Therapy for Addiction in 2026
Ibogaine, psilocybin, MDMA, ketamine — the clinical trial landscape is broader than the headlines suggest, but so are the caveats.
Body: [Balanced evidence review: psilocybin for AUD (Johns Hopkins, NYU), ibogaine for OUD (Stanford, Kentucky’s state-funded research), MDMA (field setback after 2024 FDA rejection, what changed), ketamine (already approved for depression, off-label for AUD), what the meta-analyses actually show, safety concerns, regulatory pathway. Concludes with: “promising but not yet ready for routine care.” 900 words.]
Sources Cited
- 01.Ahttps://heal.nih.govNIH HEAL
- 02.Ahttps://clinicaltrials.govClinicalTrials.gov
Filed Under
Peer-Reviewed ResearchMAT — BuprenorphineFederal
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Xylazine Wound Care Has Been Guessing — Two Baltimore Studies Just Asked the Patients Instead
A 315-person survey found 4 in 10 people who inject drugs in Baltimore have had a xylazine wound. A companion study asked them why — and pointed straight at gaps in clinician training.
Science & MedicineJUUL Is Legal Again — and the FDA's Whole Fix Is a Password Screen
The agency just authorized a new JUUL device built around an optional age-gate app, betting the benefit to adult smokers outweighs the risk to teenagers. Meanwhile the one new medicine that could actually treat nicotine addiction just got turned away — over a factory inspection.
Science & MedicineGetting High With Friends Is the Riskier Choice — If You Already Have a Problem
A September 2026 Addiction study of 104 adults found that using cannabis around other people amplifies craving and continued use, but only for those with more severe cannabis problems.